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Abstract
Background: What constitutes a "clinical trial" is inconsistently defined in the medical literature.
With an initiative by Cancer Care Ontario (CCO) to report institutional clinical trials activity
across the province of Ontario, Canada, we sought to investigate the variability in the
interpretation of the term by local oncology professionals.
Methods: A survey amongst the physicians and nurses at the Juravinski Cancer Centre at Hamilton
Health Sciences, Ontario was conducted. The survey included 12 summaries of local clinical
research studies, and respondents were asked which they believed represented a clinical trial.
Subsequently, they were asked which of the same 12 studies they believed should be labeled as
clinical trials when considering separate definitions provided by CCO and by the Ontario Cancer
Research Network (OCRN).
Results: A total of 66 (54%) of 123 surveys were completed; 32/46 (70%) by physicians, 21/59
(36%) by primary care nurses, and 13/18 (72%) by clinical trial nurses. Without a standardized
definition, all studies, 12/12, were considered to be clinical trials by at least 50% of respondents.
When provided with the CCO definition only 6/12 studies were considered to be clinical trials by
the majority of respondents, while with the OCRN definition it was 9/12 studies. Studies evaluating
natural health products, non-traditional medical interventions, and non-randomized studies with
standard interventions consistently ranked the lowest, regardless of the definition used.
Conclusion: Oncology professionals appear to have a broadly inclusive baseline definition of what
constitutes a clinical trial. Establishing rigor and consistency in the definition of a clinical trial is
important for any program, institutional or jurisdictional based comparisons of clinical trials activity,
especially when used as a quality indicator of patient care.
Background
Clinical trials are appreciated as the most important vehi-
cle by which advances in patient management occur [1].
Unfortunately only a small number of cancer patients par-
ticipate in clinical trials [2-5]. This has lead to various
national and regional strategies to try and improve overall
trials activity. Summary measures to evaluate this activity
within institutions or across jurisdictions have typically
been reported as the proportion of new patients, either
within an institution or from population based incidence
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statistics, or the number of treated patients, that are
enrolled in clinical trials [6,7]. This proportion of patients
is suggested to represent an institutional measure of qual-
ity of care, with the hypothesis that a higher proportion of
patients enrolled in clinical trials is reflective of higher
quality of care [8]. However, a number of assumptions
underlie the interpretation of such a simple summary
measure, including the ability to consistently and reliably
define the types of clinical research studies that should be
designated as "clinical trials".
Cancer Care Ontario (CCO) monitors the performance of
the cancer system in the Province of Ontario, Canada. As
part of this monitoring CCO has recently proposed
twenty-five "quality indicators" as summary measures of
the Ontario cancer system, all of which are available to the
general public [8]. One of these quality measures is the
proportion of treated cancer patients enrolled in clinical
trials. Data is available from all 12 of the regional cancer
programs across the province. The CCO website presents
their operational definition of a clinical trial as being
"treatment based; including surgery, systemic chemother-
apy and radiation therapy. Trials for cancer prevention,
screening or diagnosis are not included". CCO obtains
this data regarding trials activity from the Ontario Cancer
Research Network (OCRN), which is a not-for-profit, pro-
vincially funded organization, whose key mandate is to
increase clinical trials activity in the province of Ontario.
Many cancer programs have received infrastructure-fund-
ing support from the OCRN to increase patient accrual to
clinical trials, with the intention of doubling baseline
enrollment levels. The OCRN's definition of a clinical trial
as contained within the OCRN Clinical Trials Infrastruc-
ture Fund Policy Manual, suggests that a clinical trial is
one testing a new therapy and quotes a US based National
Institutes of Health (NIH) definition as "a research study
to answer specific questions about vaccines or new thera-
pies or new ways of using known treatments."
Given the potential for variably interpreting the above
definitions of a clinical trial, we sought to investigate the
types of clinical research that our local oncology profes-
sionals considered to be clinical trials, and how they inter-
preted the CCO and OCRN definitions in comparison.
Methods
A single institution survey was circulated by internal mail
to all physicians and nurses at the Juravinski Cancer Cen-
tre (JCC). The JCC is home to a large comprehensive
regional cancer program within Hamilton Health Sci-
ences, Hamilton, Ontario, Canada. The centre serves a
regional population of approximately 2.3 million people.
Most physicians and nurses at the JCC are responsible for
the care of patients involved in clinical research studies.
After receiving approval from our local Research Ethics
Board (REB), the survey was sent to a total of 123 individ-
uals; consisting of 46 physicians and 77 nurses of whom
18 nurses were from the clinical trials department. A cov-
ering letter explaining the survey was included (see Addi-
tional file 1). Individual survey responses were tracked
solely for the purpose of a mailed reminder to complete
the survey. A second copy was sent to non-responders
after a 6-week period.
The survey was constructed from brief descriptions of 12
previously or currently active local clinical research proto-
cols, all of which required local REB approval and signed
informed consent from the involved patients. The 12
studies were purposely selected to encompass the breath
of the active research portfolio, and to ensure various
phases and intensity of research were represented. The
study summaries were initially reviewed with two nurses
and two physicians to ensure clarity and comprehensive-
ness. The 12 studies selected included the following (with
question number in brackets, see Additional file 1):
• 2 studies evaluating new drugs or vaccines, one phase I
(Q6), the other a randomized phase III (Q11)
￿ 2 randomized studies comparing standard therapies,
both phase III (Q1, Q8)
￿ 2 studies prospectively evaluating natural products, both
phase II (Q2, Q9)
￿ 2 randomized studies evaluating medical interventions
that are not direct cancer therapies (i.e. not surgery, radia-
tion, or systemic chemotherapy), both phase III (Q10,
Q12)
￿ 2 studies prospectively evaluating non-traditional med-
ical interventions that are not cancer therapies, one phase
II (Q5), the other a randomized phase III (Q4)
￿ 2 non-randomized studies with standard interventions
prospectively correlating outcome measures (Q3, Q7)
Without providing a definition, respondents were asked
to indicate which of the 12 research summaries they
believed to be a "clinical trial". Response options included
yes, no, or unknown. Respondents were then provided
with the CCO and the OCRN definitions as quoted previ-
ously, and were again asked to assess each research sum-
mary using the definition provided. The covering page
stressed the need to complete the survey in this prescribed
order. This resulted in a total of 36 separate responses;
each study assessed without a definition; each study using
the CCO definition; and each study using the OCRN def-
inition. A full copy of the survey is available (see Addi-
tional file 1).Trials 2008, 9:12 http://www.trialsjournal.com/content/9/1/12
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Analysis
The age, gender, and profession of all respondents were
collected. Percentages were used to represent the overall
proportion of affirmative responses for each of the 12
studies, using each of the three definitions. The propor-
tion of respondents that changed a response within a
question triplet was recorded. The proportion of affirma-
tive responses for each set of 12 questions, by professional
group, was compared with Chi-squared and Fisher's Exact
Tests to determine statistically significant differences.
Exploratory analysis with t-tests and analysis of variance
were performed within and between the professional
groups.
Results
A total of 66 of the 123 (54%) surveys were returned, 32
from physicians (32/46 = 70%), 21 from primary care
nurses (21/59 = 36%), and 13 from clinical trial nurses
(13/18 = 72%). Overall the 32 physicians represented
49% of the respondents, and included 13 medical oncol-
ogists, 11 radiation oncologists, 5 surgical oncologists,
and 3 general practitioners in oncology. The primary care
nurses represented 32% of respondents, and clinical trial
nurses 20%. Fifty-one, or 77% of respondents were
between the ages of 35 and 55 years of age.
The percentages of affirmative responses for each ques-
tion, and the mean score per definition, are summarized
in Table 1. When respondents utilized their personal def-
inition of what constituted a clinical trial, all questions
were answered affirmatively by at least 50%, noting that
question 3, dealing with tumor markers, was exactly 50%.
Four other questions, specifically numbers 5, 7, 4, and 9,
in rank order of affirmative responses, had scores ranging
between 61% and 73% respectively.
When provided with the CCO definition of a clinical trial,
only half the studies were considered to represent a clini-
cal trial. Questions 5, 4, 7, 2, 3 and 9 as ranked in order of
their percent affirmative responses, were all below 50%.
While with the OCRN definition, nine of the 12 studies
were scored by more than 50% to represent a clinical trial.
Questions 4, 5, and 7 ranked below 50% with scores of
35%, 38%, and 44% respectively. When the summary of
each research project was considered in the context of all
three definitions, i.e. questions 1, 13, 25 and questions 2,
14, 26 etc each as a question triplet there were five ques-
tions (2, 4, 5, 7, 9) that had 50% or more of respondents
change at least one affirmative response based on the def-
inition in use (see Table 2). For all 12 of the question tri-
plets, on average just over one third of respondents
changed at least one response. Regardless of the definition
utilized, questions 2, 3, 4, 5, 7, and 9 consistently ranked
lowest for affirmative response scores.
Across groups, physicians and clinical trial nurses were
generally similar in their level of affirmative responses.
The primary care nurses tended to be more conservative
with fewer affirmative responses. Using their personal def-
inition of a clinical trial, they scored significantly lower
than both physicians and trial nurses, or physicians alone
for questions 2, 4, 5, 6, and 8 (see Table 3). Analysis of
variance for profession, gender and age, found only pro-
fessional group was significant for the rates of positive
responses. Analysis within the three definitions separately
found that profession predicted differences only with the
personal and CCO definitions, but not the OCRN defini-
tion (only data for the personal definition is presented in
Table 3). Within the physician and nursing groups there
was no gender or age effects noted.
Discussion
This survey illustrates a number of important issues. First,
that there is variability in what oncology professionals
personally define as being a clinical trial. Nine of the 12
research summaries had less than 90% affirmative
Table 1: Affirmative Response Rates by Study by Each Definition (n = 66)
Definition Personal (Q1–12) CCO (Q13–24) OCRN (Q25–36)
Questions
Q1, 13, 25 97% 94% 92%
Q2, 14, 26 86% 44% 71%
Q3, 15, 27 50% 49% 50%
Q4, 16, 28 67% 29% 35%
Q5, 17, 29 61% 21% 38%
Q6, 18, 30 89% 88% 96%
Q7, 19, 31 64% 41% 44%
Q8, 20, 32 89% 83% 88%
Q9, 21, 33 73% 49% 70%
Q10, 22, 34 89% 62% 80%
Q11, 23, 35 97% 97% 99%
Q12, 24, 36 92% 73% 83%
Mean 80% 61% 68%Trials 2008, 9:12 http://www.trialsjournal.com/content/9/1/12
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responses, and four had between 50% and 67% with
affirmative responses, suggesting at least some degree of
collective uncertainty. Secondly, simple nuances in the
definition of a clinical trial can have a major impact on
the interpretation of whether the described research study
constitutes a clinical trial or not. In this survey, on average,
over one third of respondents changed at least one of their
responses for each study based on the applied definition.
Perhaps not surprisingly, given the focus on treatment
based clinical trials, the operationalized CCO definition
as provided to respondents was the most strictly inter-
preted, as only 6/12 studies were considered to represent
clinical trials by the majority of respondents, vs. 9/12 with
the OCRN definition, and 12/12 without a standardized
definition. Thirdly, as the preceding ratios demonstrate,
most oncology professionals have a personal definition of
a clinical trial that is broadly inclusive of most clinical
research.
The research studies that consistently ranked the lowest in
all situations included studies evaluating natural products
(questions 2 and 9), non-traditional medical interven-
tions (questions 4 and 5), and studies with standard inter-
ventions and no prospective comparison groups
(questions 3 and 7). In part this likely reflects a bias
towards the traditional medical model of investigational
therapeutics.
This variability interpreting what constitutes a clinical trial
is not surprising. At one extreme, a strict interpretation of
the Health Canada or the Food and Drug Administration
(FDA) regulations is that clinical trials are research studies
evaluating new drugs, or vaccines, or new indications for
such existing agents. In Canada, only these types of
research studies require a "No Objection Letter" from
Health Canada after a Clinical Trial Application (CTA)
outlining the proposed research is submitted and
reviewed. Research studies comparing standard therapies,
Table 2: Proportion of Respondents (n = 66) that Changed at Least one Response per Question Triplet
Question Triplets % Changed Responses
Q1, 13, 25 14%
Q2, 14, 26 56%
Q3, 15, 27 39%
Q4, 16, 28 62%
Q5, 17, 29 56%
Q6, 18, 30 17%
Q7, 19, 31 56%
Q8, 20, 32 21%
Q9, 21, 33 50%
Q10, 22, 34 36%
Q11, 23, 35 3%
Q12, 24, 36 27%
Mean 36.5%
Table 3: Affirmative Response Rates for Personal Definitions by Study by Professional Groups
Physician (n = 32) Clinical Trial Nurse (n = 13) Other Nurses (n = 21)
Questions
Q1 100% 100% 91%
Q2 100% 100% 57%*
Q3 47% 69% 43%
Q4 84% 62% 43%**
Q5 72% 69% 38%**
Q6 100% 100% 67%*
Q7 63% 69% 62%
Q8 100% 92% 71%**
Q9 81% 77% 57%
Q10 94% 92% 81%
Q11 100% 100% 91%
Q12 97% 100% 81%
Mean 87% 86% 65%
* Significantly lower than both physicians and clinical trial nurses (p < 0.05)
** Significantly lower than physicians alone (p < 0.05)Trials 2008, 9:12 http://www.trialsjournal.com/content/9/1/12
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or approved agents such as radiation therapy, regardless of
the dose, do not require a similar level of federal review.
But this narrow pharmacologically based interpretation
does not appear to be widely utilized. In a recent editorial
outlining the rational for the registration of future clinical
trials, the International Committee of Medical Journal
Editors have defined a clinical trial as "any research
project that prospectively assigns human subjects to inter-
vention and comparison groups to study the cause-and-
effect relationship between a medical intervention and a
health outcome" [9]. While an intervention in this context
is broadly defined to include drugs, surgical procedures,
devices, behavioral treatments, process-of-care changes
and the like, the definition is clearly limited to rand-
omized phase III trials. Others such as Pocock, have sug-
gested that a clinical trial is "any form of a planned
experiment which involves patients and is designed to
elucidate the most appropriate treatment of future
patients with a given medical condition", specifically
including classic phase I and II trials within this definition
[10].
In oncology, various definitions and classification
schemes for clinical trials exist. The US National Cancer
Institute (NCI) website suggests, "clinical trials are
research studies in which people help doctors find ways to
improve health and cancer care" [11]. The NCI classifies
clinical trials as treatment trials, prevention trials, screen-
ing trials, diagnostic trials, genetics trials, and quality of
life trials. Quality of life trials, also referred to as support-
ive care trials, are described as trials "to reduce side effects
from primary treatments, other symptoms, and the bene-
ficial effects of nutrition, group therapy and other
approaches". The NCI website suggests that population
and family-based genetic research studies are not cancer
clinical trials as traditionally defined. In distinction how-
ever, the ClinicalTrials.gov website, supported as a service
of the US NIH more broadly defines a clinical trial as a
research study in human volunteers to answer specific
health questions, and categorizes trials as interventional,
or observational. Observational trials are defined as trials
that address health issues in large groups of people or
populations in natural settings [12]. This definition
would suggest that studies involving tumour banking,
without a planned intervention per se would be consid-
ered as clinical trials if they follow a pre-defined protocol.
Some ambiguity is even reflected in the web sites of spe-
cific cancer treatment Programs. At MD Anderson for
example, clinical trials are defined as "strictly controlled
human studies of new and emerging therapies". Yet, the
largest treatment category listed under active clinical trials
on their website is "no treatment" [13].
This survey was limited in scope and complexity. The pur-
poseful sampling of research projects accentuates the true
variation that would result from nuances of a definition of
a clinical trial, and the total scores per definition have lit-
tle inherent meaning. Respondents, while discouraged
from doing so, had the opportunity to read through the
entire survey prior to completing the sections in the pre-
scribed order. Such activity however, would have likely
resulted in less, not more variation in their responses.
Despite a second mailing the survey was only completed
by 54% of the solicited physicians and nurses. From a
phenomenistic perspective, many of the primary care
nurses informally noted concern with the apparent com-
plexity of the survey and the perception of a large time
requirement. A well-accepted trials definition may have
facilitated more timely completion. Physicians and clini-
cal trial nurses are most directly involved in clinical
research, and were the groups most likely to complete the
questionnaire, and perhaps as a bias of their positions
they also tended to report a higher proportion of affirma-
tive responses. Within these two groups the response rate
was a more compelling 70 plus percent. A larger survey
would seem unlikely to either result in different conclu-
sions or remove the need to develop and utilize a robust
definition of what constitutes a "clinical trial".
Conclusion
The intent of this survey was not to develop a definition
of what constitutes a clinical trial, but rather to illustrate
the importance of doing so. If oncology professionals
within the same institution are not consistent with their
interpretation of what constitutes a clinical trial it would
seem unlikely that health care administrators or the pub-
lic at large would have a meaningful appreciation of the
issues. It is not always clear how investigators or clinical
research programs have defined a clinical trial when
reporting their rates of clinical trials activity. A meaningful
and consistently applied definition of a clinical trial is
important to establish as programmatic and institutional
activity summaries are generated across the province of
Ontario and beyond. Such comparisons may facilitate a
broader understanding of the recruitment process. Even
local trends in clinical trials recruitment must be exam-
ined with a consistently applied definition if the recruit-
ment process is to be better understood and improved.
Before interpreting any recent improvements in patient
recruitment, it is important to ensure that changes are not
simply a function of a more inclusive definition of a clin-
ical trial. A consistent definition of a clinical trial is not an
issue unique to oncology, as all investigators with an
interest in improving the metrics of patient participation
in clinical research need to be speaking the same lan-
guage.
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